EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA
Chowdhury T, Johnson K, Kocakavuk E, Heo C, Ye G, Ghospurkar P, Wade T, Barnholtz-Sloan J, Costello J, Elliott C, French P, Golebiewska A, Hermes B, Hong C, Horbinski C, Khasraw M, LaViolette P, Li K, Lipp E, Lowman A, McCortney K, Moon H, Ng H, Padovan M, Paek S, Vallentgoed W, Vaubel R, Wesseling P, Westcott K, Consortium G, Varn F, Verhaak R. EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA. Neuro-Oncology 2023, 25: v128-v128. PMCID: PMC10639435, DOI: 10.1093/neuonc/noad179.0485.Peer-Reviewed Original ResearchWhole-exome sequencingPI3K pathwaySingle-nucleus RNA sequencingStem-like cellsPatient mortalityChromosome 4 lossPIK3R1 mutationsTreatment resistanceFUBP1 mutationsAggressive phenotypeMost oligodendrogliomasOligodendroglioma patientsChromosome arms 1pRecurrenceAdministration dateSomatic copy number alterationsCopy number alterationsMutational signature analysisOligodendrogliomasRecurrent samplesTERT promoterExome sequencingK pathwayCommon mutationsMolecular changesEPCO-37. DISSECTING GBM EVOLUTION FOLLOWING STANDARD-OF-CARE BY LARGE-SCALE LONGITUDINAL SINGLE NUCLEUS RNA-SEQUENCING
Nomura M, Spitzer A, Johnson K, Garofano L, Nehar-Belaid D, Oh Y, Anderson K, Najac R, Bussema L, Varn F, D’Angelo F, Chowdhury T, Migliozzi S, Park J, Ermini L, Golebiewska A, Niclou S, Das S, Paek S, Moon H, Mathon B, Di Stefano A, Bielle F, Laurenge A, Sanson M, Tanaka S, Saito N, Keir S, Ashley D, Huse J, Yung W, Lasorella A, Iavarone A, Verhaak R, Suva M, Tirosh I. EPCO-37. DISSECTING GBM EVOLUTION FOLLOWING STANDARD-OF-CARE BY LARGE-SCALE LONGITUDINAL SINGLE NUCLEUS RNA-SEQUENCING. Neuro-Oncology 2023, 25: v132-v132. PMCID: PMC10639295, DOI: 10.1093/neuonc/noad179.0499.Peer-Reviewed Original ResearchSingle-nucleus RNA sequencingLarge-scale longitudinal cohortTME compositionRecurrent samplesGood clinical courseInitial tumor resectionMajority of patientsTumor microenvironment cellsPrimary tumor samplesMGMT methylation statusTME changesClinical courseRNA sequencingTherapy failureLikely respondersTumor resectionDisease progressionNucleus RNA sequencingLongitudinal cohortReciprocal increaseTumor samplesMicroenvironment cellsMalignant cell fractionGlioblastomaRecurrence